Nicolas Coudurier – CEO, Biocodex
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Address: rue des Trois Arbres 16, 1180 Brussels, Belgium
Tel: +32 (0)2 370 47 90
Biocodex is an independent, family-owned French pharmaceutical company founded in 1953 by Michel Hublot and François Vallet.
Our mission is to develop and make accessible to doctors and their patients, effective and safe products which improve the health and quality of life of patients.
> Our pledge: to always be at the service of the patient.
> Our commitment: to develop specific and original products.
> Our priority: to target our products on the best therapeutic indications, with the greatest tolerance/efficiency benefit.
> Our outlook: to always work toward the long term.
Biocodex is specialised in:
Gastroenterology,
Neurology & Psychiatry,
Pain Treatment,
Treatment of degenerative osteoarthritis.
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
Although Biocodex has a commercial presence in over 100 countries, it currently operates only five subsidiaries, one of them being Biocodex Belgium. What were primary motivating factors behind this strategic…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Paul Newton of Vertex Pharmaceuticals – one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry – outlines the company’s footprint…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter…
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the…
Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally…
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years,…
Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV,…
Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure,…
See our Cookie Privacy Policy Here
